U.S. Markets closed

Cascadian Therapeutics, Inc. (CASC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.940.00 (0.00%)
At close: 4:00PM EDT

3.94 0.00 (0.00%)
After hours: 4:00PM EDT

People also watch
DRNAADVMABUSCCXICHMA

Cascadian Therapeutics, Inc.

2601 Fourth Avenue
Suite 500
Seattle, WA 98121
United States
206-801-2100
http://www.cascadianrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees57

Key Executives

NameTitlePayExercisedAge
Mr. Scott D. MyersPres, CEO & Director744.57kN/A51
Ms. Julia M. Eastland M.B.A.CFO, Chief Bus. Officer & Sec.467.44kN/A53
Mr. Gary W. Christianson PEChief Operating Officer443.02kN/A62
Dr. Scott Robert Peterson Ph.D.Chief Scientific Officer494.44kN/A55
Dr. Gwen A. Fyfe M.D.Consultant & Director48.9kN/A65
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology. The company was formerly known as Oncothyreon Inc. and changed its name to Cascadian Therapeutics, Inc. in June 2016. Cascadian Therapeutics, Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Corporate Governance

Cascadian Therapeutics, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.